Paolo Ossola

Dr. Paolo Ossola


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
POPaolo Ossola
Paolo Ossola
SGSimone Ghidini
Simone Ghidini
EGElena Gualini
Elena Gualini
FDFrancesca Daus
Francesca Daus
FPFrancesco Politi
Francesco Politi
CGCristina Giannattasio
Cristina Giannattasio
Aortic stenosis (AS) is the most prevalent valvular heart disease in Western countries and it is especially associated with older age. With its progressive course, AS leads to ventricular hypertrophy, impaired diastolic and systolic function, and symptomatic deterioration. The natural history of AS is closely linked to the extent of myocardial and extracardiac damage in association with the patients comorbidities. Diagnosis relies primarily on transthoracic echocardiography, which assesses valve morphology, quantifies stenosis severity, and evaluates cardiac remodeling. However, discordant grading is frequent, necessitating advanced imaging to clarify the severity and the mechanism of the stenosis and stratify risk. Treatment is predominantly interventional, as no medical therapy is able to stop disease progression. Surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) are the two treatment options. Special clinical scenarios—such as cardiogenic shock or concomitant cardiac amyloidosis—pose additional diagnostic and therapeutic challenges and require individualized, multidisciplinary management. Overall, contemporary AS care increasingly integrates multimodality imaging, refined risk stratification, and tailored interventional strategies to optimize outcomes.

13 May 2025 in Journal of Cardiovascular Medicine
Verified
Journal Article
Closed access
POPaolo Ossola
Paolo Ossola
CCClaudio Ciampi
Claudio Ciampi
ACAndrea Cesari
Andrea Cesari
LVLuca Villanova
Luca Villanova
NGNiccolò Grieco
Niccolò Grieco
FOFabrizio Oliva
Fabrizio Oliva
Factor XI (FXI) is one of the components of the coagulation cascade, connecting its intrinsic and common pathway. FXI inhibitors have emerged in these few years as interesting therapeutic drugs, with potential advantages over standard anticoagulants in terms of lowering thrombotic risk and limiting bleeding consequences. Better knowledge of the underlying processes of thrombosis led to the design of several clinical trials based on the inhibition of this factor. The discovery of molecules, antibodies, and antisense oligonucleotides capable of binding to this factor is paving the way for new anticoagulation strategies, which will be analyzed in this review.